Canadian Thoracic Society Asthma Management Continuum –
2010 Consensus Summary for children six years of age and over, and adults Canadian Thoracic Society Asthma
Browsing Posts tagged adults
The Pharmacy Department recently received a letter from Sanofi-Aventis stating that Vaponefrin (Racemic Epinephrine) will be discontinued from the market. Currently, there is no other racemic epinephrine 2.25% product available.
The alternative for use as nebulized epinephrine therapy is Epinephrine 1:1000 solution (Adrenalin Topical Solution). Please note the difference in concentration from 2.25% to 0.1%.
Recommended Dose:
Pediatrics:
” Less than 4 years old: 2.5 mL epinephrine 1:1000 per dose (delivers 2.5 mg epinephrine).
This may be further diluted to 4-5 mL with normal saline.
” 4 years or older: 5 mL epinephrine 1:1000 per dose (delivers 5 mg of epinephrine). No need to further dilute this dose.
Adults:
” 5 mL epinephrine 1:1000 per dose (delivers 5 mg of epinephrine). No need to further dilute this dose.
Dosing Intervals:
” Same as for racemic epinephrine
Availability:
” Epinephrine 1:1000 is available as a nasal solution (Adrenalin Topical solution) ” We will be changing wardstock over to the new product on Thurs. March 15, 2007.
GlaxoSmithKline Plc’s widely prescribed drug Advair is safe enough for treating asthma but two lesser-used medicines are too risky, a U.S. advisory panel ruled on Thursday. Evidence of asthma-related deaths and serious complications led the panel of experts to warn against continued use of Glaxo’s Serevent and Novartis AG’s Foradil for adults, adolescents and children with asthma.
